Evidence map›Paper›PMID 36972959›Full record

ArticleBMJ open2023

Liying Dai, Tashi Dorje, Jan Gootjes, Amit Shah, Lawrence Dembo, Jamie Rankin, Graham Hillis, Suzanne Robinson, John J Atherton, Angela Jacques and 2 more

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Liying DaiCurtin School of Allied Health, Curtin University, Perth, Western Australia, Australia.ORCID 0000-0002-7843-6344
Tashi DorjeDepartment of Cardiology, Mount Hospital, Perth, Western Australia, Australia.
Jan GootjesWA Cardiology, Perth, Western Australia, Australia.
Amit ShahDepartment of Cardiology and Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
Lawrence DemboDepartment of Cardiology and Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
Jamie RankinDepartment of Cardiology and Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
Graham HillisDepartment of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia.ORCID 0000-0003-2417-4673
Suzanne RobinsonCurtin School of Population Health, Curtin University, Perth, Western Australia, Australia.ORCID 0000-0001-5703-6475
John J AthertonDepartment of Cardiology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.ORCID 0000-0003-2271-578X
Angela JacquesCurtin School of Allied Health, Curtin University, Perth, Western Australia, Australia.
Christopher M ReidCurtin School of Population Health, Curtin University, Perth, Western Australia, Australia.
Andrew MaioranaCurtin School of Allied Health, Curtin University, Perth, Western Australia, Australia A.Maiorana@curtin.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGeneral practitioners (GPs) routinely provide care for patients with heart failure (HF); however, adherence to management guidelines, including titrating medication to optimal dose, can be challenging in this setting. This study will evaluate the effectiveness of a multifaceted intervention to support adherence to HF management guidelines in primary care. METHODS AND ANALYSIS: We will undertake a multicentre, parallel-group, randomised controlled trial of 200 participants with HF with reduced ejection fraction. Participants will be recruited during a hospital admission due to HF. Following hospital discharge, the intervention group will have follow-up with their GP scheduled at 1 week, 4 weeks and 3 months with the provision of a medication titration plan approved by a specialist HF cardiologist. The control group will receive usual care. The primary endpoint, assessed at 6 months, will be the difference between groups in the proportion of participants being prescribed five guideline-recommended treatments; (1) ACE inhibitor/angiotensin receptor blocker/angiotensin receptor neprilysin inhibitor at least 50% of target dose, (2) beta-blocker at least 50% of target dose, (3) mineralocorticoid receptor antagonist at any dose, (4) anticoagulation for patients diagnosed with atrial fibrillation, (5) referral to cardiac rehabilitation. Secondary outcomes will include functional capacity (6-minute walk test); quality of life (Kansas City Cardiomyopathy Questionnaire); depressive symptoms (Patient Health Questionnaire-2); self-care behaviour (Self-Care of Heart Failure Index). Resource utilisation will also be assessed. ETHICS AND DISSEMINATION: Ethical approval was granted by the South Metropolitan Health Service Ethics Committee (RGS3531), with reciprocal approval at Curtin University (HRE2020-0322). Results will be disseminated via peer-reviewed publications and conferences. TRIAL REGISTRATION NUMBER: ACTRN12620001069943.

Indexed as

Cardiac RehabilitationHeart FailureHumansMulticenter Studies as TopicPrimary Health CareQuality of LifeRandomized Controlled Trials as TopicSelf CareClinical trialsHeart failurePRIMARY CARE

Identifiers

PMID36972959
PMCPMC10069547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.